Evrysdi — risdiplam
Named-patient access overview. Evrysdi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Evrysdi
Evrysdi (risdiplam) is manufactured by Roche/PTC and indicated for SMA all ages. It is a SMN2 splicing mod. approved by the US FDA in 2020 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Evrysdi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Evrysdi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Evrysdi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Evrysdi in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Evrysdi in BahrainNamed-patient access, timeline, and regulatory notes
Evrysdi in IndiaNamed-patient access, timeline, and regulatory notes
Evrysdi in KuwaitNamed-patient access, timeline, and regulatory notes
Start a request for Evrysdi
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.